02 Sept 2021
Following clinical trials showing high effectiveness for inclisiran in treating heart disease, it has now been approved for use by NHS England. The twice yearly injection targets high cholesterol through RNA interference and is expected to prevent early deaths from heart disease and stroke.
NEW Research SIG
07 Jan 2025
ISE selects Bioscientifica as its association management provider
01 Jan 2025
Division Chief of Endocrinology
01 Jan 2025
Society members recognised in New Year Honours List
01 Jan 2025